Results 161 to 170 of about 8,086 (190)

Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images. [PDF]

Mol Cancer Res
Omar M, Xu Z, Rand SB, Alexanderani MK, Salles DC, Valencia I, Schaeffer EM, Robinson BD, Lotan TL, Loda M, Marchionni L.   +10 more
europepmc   +1 more source

Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis. [PDF]

Mol Carcinog
Prasad RR, Mishra N, Kant R, Fox JT, Shoemaker RH, Agarwal C, Raina K, Agarwal R.   +7 more
europepmc   +1 more source

Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes [PDF]

, 2014

core   +1 more source

Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status. [PDF]

BMC Cancer, 2020
Dudka I, Thysell E, Lundquist K, Antti H, Iglesias-Gato D, Flores-Morales A, Bergh A, Wikström P, Gröbner G.   +8 more
europepmc   +1 more source

Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. [PDF]

Pathol Oncol Res, 2020
Bernreuther C, Daghigh F, Möller K, Hube-Magg C, Lennartz M, Lutz F, Rico SD, Fraune C, Dum D, Luebke AM, Eichenauer T, Möller-Koop C, Schlomm T, Wittmer C, Huland H, Heinzer H, Graefen M, Haese A, Burandt E, Tsourlakis MC, Clauditz TS, Höflmayer D, Izbicki JR, Simon R, Sauter G, Minner S, Steurer S, Meiners J.   +27 more
europepmc   +1 more source

The Role of AMACR, CD10, TMPRSS2-ERG, and p27 Protein Expression Among Different Gleason Grades of Prostatic Adenocarcinoma on Needle Biopsy. [PDF]

Clin Med Insights Oncol, 2020
Gülhan Ö, Mahi B.
europepmc   +1 more source

Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. [PDF]

Mol Med, 2020
Fraune C, Harms L, Büscheck F, Höflmayer D, Tsourlakis MC, Clauditz TS, Simon R, Möller K, Luebke AM, Möller-Koop C, Steurer S, Hube-Magg C, Sauter G, Weidemann S, Lebok P, Dum D, Kind S, Minner S, Izbicki JR, Schlomm T, Huland H, Heinzer H, Burandt E, Haese A, Graefen M, Schroeder C.   +25 more
europepmc   +1 more source

Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. [PDF]

Prostate, 2020
Shao L, Kahraman N, Yan G, Wang J, Ozpolat B, Ittmann M.   +5 more
europepmc   +1 more source

Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. [PDF]

Virchows Arch, 2020
Möller K, Wecker AL, Höflmayer D, Fraune C, Makrypidi-Fraune G, Hube-Magg C, Kluth M, Steurer S, Clauditz TS, Wilczak W, Simon R, Sauter G, Huland H, Heinzer H, Haese A, Schlomm T, Weidemann S, Luebke AM, Minner S, Bernreuther C, Bonk S, Marx A.   +21 more
europepmc   +1 more source

TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa. [PDF]

Prostate, 2019
Blackburn J, Vecchiarelli S, Heyer EE, Patrick SM, Lyons RJ, Jaratlerdsiri W, van Zyl S, Bornman MSR, Mercer TR, Hayes VM.   +9 more
europepmc   +1 more source